Skip to main content
TipRanks
Go Ultimate75% OFF

Great Tree Pharmacy Co., Ltd. (6469) AI Stock Analysis

TW:6469

Great Tree Pharmacy Co., Ltd.

(TPEx:6469)

Select Model
Rating:56Neutral
Price Target:TWD 60.00â–²(3.81% Upside)
Action:initiatedcoverage
Date:11/09/26

Great Tree Pharmacy scores in the middle of the range. Financial fundamentals are the dominant driver: strong revenue growth, improving gross margins and consistently positive free cash flow are genuine strengths, but shrinking operating and net margins, three straight years of lower net income, and debt at roughly 1.8x equity with weakening cash coverage are material risks. Technicals are the biggest drag — the shares sit well below all major moving averages with negative MACD, and while deeply oversold readings suggest the move is extended, there is no confirmation of a turn. Valuation provides the main offset, with a moderate 17.1x P/E and an attractive 5.46% dividend yield, although payout sustainability warrants monitoring given the earnings trend. Low beta (0.12) means the stock's weakness is company-specific rather than market-driven.

Positive Factors
Multi-year revenue growthSustained revenue expansion indicates that Great Tree continues to grow its community-pharmacy retail base and customer demand over multiple years. The additional increase in 2025 supports ongoing business momentum and provides a durable foundation for maintaining scale, funding operations, and supporting future profitability.
Negative Factors
Elevated and rising leverageRising debt relative to equity increases the company’s financial leverage and reduces flexibility if earnings soften. Because Great Tree operates in a defensive healthcare retail sector, the balance-sheet profile being more levered than ideal may constrain future investment choices and make periods of weaker performance harder to absorb.

Great Tree Pharmacy Co., Ltd. (6469) vs. SPDR S&P 500 ETF (SPY)

-40%-30%-20%-10%0%10%20%TW:6469-38.59%SPY+10.92%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
TWD 9.11B
Dividend Yield
5.46%
Average Volume (3M)
401.78K
Price to Earnings (P/E)
16.6
Beta (1Y)
0.12
Revenue Growth
4.00%
EPS Growth
-25.06%
Country
TW
Employees
446
Sector
General
Sector Strength
55
Industry
Medical - Pharmaceuticals

Great Tree Pharmacy Co., Ltd. Business Overview & Revenue Model

Company Description

Great Tree Pharmacy Co., Ltd. is a Taiwanese enterprise that operates an extensive chain of pharmacies throughout the island nation. These retail outlets offer a broad selection of goods, including prescription and over-the-counter medications, nutri...

Great Tree Pharmacy Co., Ltd. Financial Statement Overview

Summary

Mixed quality. Revenue has compounded at roughly 17% annually since 2020 (NT$8.6bn to NT$18.9bn) with gross margin improving to 28.7%, and cash generation is solid — operating cash flow of NT$1.17bn and a sixth straight year of positive free cash flow (NT$787m). Offsetting this, operating margin has fallen from 6.4% to 4.4%, net income has declined for three consecutive years, and leverage is elevated at ~1.8x debt-to-equity with equity funding only ~28% of assets. Return on equity remains respectable at 15.3% but has dropped sharply from 26.9% in 2022, indicating the store-expansion strategy is delivering diminishing returns.

Income Statement

64Positive

Balance Sheet

48Neutral

Cash Flow

69Positive
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue19.02B18.90B17.27B16.14B14.56B11.28B
Gross Profit5.43B5.42B4.84B4.49B4.01B2.94B
EBITDA1.52B1.71B1.71B1.60B1.54B1.04B
Net Income515.77M600.42M680.77M666.05M700.07M407.42M
Balance Sheet
Total Assets14.02B13.76B12.13B10.77B10.12B7.39B
Cash, Cash Equivalents and Short-Term Investments2.53B2.54B2.23B2.16B2.48B1.33B
Total Debt6.44B7.07B6.00B5.14B5.13B3.83B
Total Liabilities10.28B9.76B8.48B7.42B7.49B5.44B
Stockholders Equity3.67B3.92B3.60B3.28B2.60B1.93B
Cash Flow
Free Cash Flow623.39M787.01M779.64M564.03M910.93M823.18M
Operating Cash Flow965.15M1.17B1.14B890.33M1.23B1.08B
Investing Cash Flow-684.52M-880.71M-881.37M-416.53M-465.58M-268.43M
Financing Cash Flow-597.02M-409.63M-499.08M-795.84M389.10M-336.57M

Great Tree Pharmacy Co., Ltd. Peers Comparison

Overall Rating

UnderperformOutperform
Sector (55)

Financial Indicators

TW:6469 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
TW:1203TW:120370OutperformTWD 10.47B21.08―2.27%-13.42%12.83%
TW:6790TW:679068NeutralTWD 9.84B11.96―7.19%-3.83%17.72%
TW:6534TW:653467NeutralTWD 8.35B15.17―6.17%6.31%31.07%
TW:8436TW:843662NeutralTWD 10.68B9.60―6.52%-3.82%2.23%
TW:6469TW:646956NeutralTWD 9.20B16.65―5.46%4.00%-25.06%
Sector *55Neutral$6.65B3.83-15.92%6.20%10.91%7.18%
TW:1702TW:170243NeutralTWD 7.65B46.74―5.19%-0.31%-90.22%

* General Sector Average

Performance Comparison

-20%0%20%TW:6469TW:1203TW:1702TW:6534TW:6790TW:8436Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
TW:6469 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
TW:6469Great Tree Pharmacy Co., Ltd.57.80-36.31-38.59%
TW:1203Ve Wong Corporation44.055.2513.52%
TW:1702Namchow Holdings Co., Ltd.30.85-6.87-18.22%
TW:6534CH Biotech R&D Co., Ltd.86.00-4.67-5.15%
TW:6790Yuen Foong Yu Consumer Products Co., Ltd.36.851.424.02%
TW:8436TCI Co., Ltd.92.20-24.45-20.96%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 09, 2026